

Concise synthesis of dideoxy-epigallocatechin gallate (DO-EGCG) and evaluation of its anti-influenza virus activity

Takumi Furuta,^{a,*} Yasuo Hirooka,^a Ayako Abe,^a Yusuke Sugata,^a Mitsuru Ueda,^a Kouki Murakami,^b Takashi Suzuki,^b Kiyoshi Tanaka^a and Toshiyuki Kan^{a,*}

^aDepartment of Synthetic Organic & Medicinal Chemistry, School of Pharmaceutical Sciences, University of Shizuoka, 52-1 Yada, Suruga-ku, Shizuoka 422-8526, Japan

^bDepartment of Biochemistry, School of Pharmaceutical Sciences, University of Shizuoka, CREST, JST, and COE Program in the 21st Century, 52-1 Yada, Suruga-ku, Shizuoka 422-8526, Japan

Received 2 February 2007; revised 12 March 2007; accepted 13 March 2007

Available online 16 March 2007

This paper is dedicated to the memory of the late Professor Kiyoshi Tanaka, who passed away on December 8, 2004.

Abstract—Dideoxy-epigallocatechin gallate (DO-EGCG) (**2**), a simplified analog of naturally occurring EGCG (**1**), was efficiently prepared by directly introducing a ketone group at C3 and successive reduction to the *sec*-alcohol with 2,3-*cis* stereochemistry. Compound **2** showed potent anti-influenza virus activity, indicating that the hydroxyl substituents on the A-ring are not crucial for anti-influenza virus activity.

© 2007 Elsevier Ltd. All rights reserved.

(–)-Epigallocatechin gallate (EGCG) (**1**),¹ which is a major constituent of green tea extract, has received special attention for its cancer preventive,² antiviral³, and other important bioactivities.⁴ Although **1** is expected to be a promising candidate for drug development, the structure–activity relationship of **1** has not been sufficiently investigated due to the limited availability of EGCG derivatives, which are mainly provided from natural sources. Furthermore, selectively modifying the densely substituted hydroxyl groups of **1** is difficult.

Among the naturally occurring stereoisomeric catechins, including (+)-catechin (2,3-*trans*), compound **1**, which possesses 2,3-*cis* stereochemistry, exhibits the most potential bioactivities.

Therefore, an easy route to structurally diversified EGCG analogs is needed.⁵ However, examples of a selective synthesis of **1** and its related derivatives are limited due to the difficulty of selectively constructing 2,3-*cis* stereogenic centers on a C-ring where the chiral center at the C2 position is easily epimerized under basic conditions.^{5,6}

Because epigallocatechin derivative **3** should be easily installed by the reduction of the ketone functional group at C3, compound **4** should be a key intermediate.⁷ Ketone **4** may be directly prepared from nitrochromene derivative **5**, which possesses a tricyclic system that corresponds to the A, B, and C-rings of the catechin framework. We envisioned that nitrochromene **5** may be constructed by the ring formation between two segments, salicylaldehyde (**6**) and nitroolefin derivative **7**. This divergent synthesis may be applicable to EGCG related derivatives (Scheme 1).


During the course of our investigation, we concisely synthesized dideoxy-epigallocatechin gallate (DO-EGCG) (**2**). Moreover, we found that **2** exhibits potent anti-influenza virus activity, although this analog has simplified structure of **1** without the phenolic hydroxyl groups on the A-ring. Herein, the detailed synthesis of **2** and the preliminary investigation of its anti-influenza virus activity are described (Fig. 1).

Initially a one-pot nitroaldol and dehydration reaction of 3,4,5-tribenzyloxybenzaldehyde (**8**)^{5b} with nitromethane under Knoevenagel conditions was performed to afford desired **9** in good yield (Scheme 2).

The successive ring construction between **9** and **6** in the presence of a catalytic amount of DABCO⁸ was

Keywords: Epigallocatechin gallate; Nitrochromene derivative; Neg reaction; Anti-influenza virus activity.

* Corresponding authors. E-mail: furuta@u-shizuoka-ken.ac.jp



Scheme 1. Synthetic strategy.




Figure 1. EGCG (1) and dideoxy-EGCG (2).

achieved via a formal oxy-conjugate addition of the phenolic hydroxyl group of **6** to **9**, and subsequent nitroaldol and condensation reactions gave desired nitrochromene derivative **10** in moderate chemical yield.⁹

Next, we focused on the direct transformation of the nitroolefin moiety to the ketone functional group. Although several Nef-type reactions are available for the transformation,¹⁰ only reductive conditions with TiCl_3 ¹¹ reliably afforded ketone derivative **11** without the oxime intermediate.^{12,13} Ketone **11** was relatively

unstable under atmospheric conditions, the product from the TiCl_3 reaction was directly subjected without purification to further reduction with L-Selectride to give **12** as a single product with the desired stereochemistry.¹⁴ The relative configuration of **12** was confirmed by the coupling constant for the protons at C2 and C3 on ^1H NMR.⁶

After condensation with 3,4,5-tribenzyloxybenzoic acid (**13**),¹⁵ all of the benzyl groups were removed under catalytic hydrogenation conditions with $\text{Pd}(\text{OH})_2$ to afford **2**,¹⁶ which cannot be theoretically obtained through a polyketide biosynthetic pathway.


Because EGCG is known to possess anti-influenza virus activity,^{3a} we then moved to a preliminary evaluation of the activity of **2**.¹⁷ As shown in Table 1, catechin **2** showed a potent inhibitory effect of the infection of the influenza virus (A/memphis/1/71, H3N2) to MDCK cells with 11.92 μM of IC_{50} , which is three times higher than that of **1** (IC_{50} : 41.25 μM). This result suggests that the hydroxyl groups on the A-ring are unnecessary for the inhibition of the influenza virus infection.

Furthermore, considering this potent bioactivity, further chemical modifications such as introducing a biotin tag and/or photoactivatable groups such as benzophenone might be possible on the A-ring without losing the bioactivities.¹⁸ This is advantageous for further development of EGCG probe molecules.

Table 1. Inhibition of influenza A virus infection to MDCK cells

Compound	Complement inhibition IC_{50}^a (μM)
2	11.92 (± 4.50)
EGCG (1)	41.25 (± 15.45)


^a Values are means of three experiments, standard deviation is given in parentheses.



Scheme 2. Preparation of dideoxy-EGCG (**2**). Reagents and conditions: (a) CH_3NO_2 (3.0 equiv), piperidine (3.0 equiv), AcOH (3.0 equiv), toluene, 80 °C, 63%; (b) salicylaldehyde (**6**) (1.5 equiv), DABCO (10 mol%), CH_2Cl_2 , sealed tube, 60 °C, 54%; (c) TiCl_3 (5.0 equiv), AcONH_4 (2.0 equiv), 1,4-dioxane–50% AcOH (5:1), rt; (d) L-Selectride (2.0 equiv), THF, rt, 38% (2 steps); (e) 3,4,5-tribenzyloxybenzoic acid (**13**) (1.0 equiv), EDCI (1.5 equiv), DMAP (0.1 equiv), CH_2Cl_2 , rt, 69%; (f) $\text{Pd}(\text{OH})_2$, H_2 , THF–MeOH (5:1), rt, 57%.


In conclusion, the synthesis of EGCG analog **2** has been performed via a concise synthetic route with the selective construction of the 2,3-*cis* stereochemistry. The methodology presented here should be easily applicable to further functionalized analogs. Thus, this methodology should promote a detailed structure–activity relationship study. Further preparation of EGCG derivatives, investigation of the anti-influenza virus activity mechanism, and a survey of other bioactivities such as anti-Alzheimer's disease effect⁴ are currently underway.

References and notes



- For a review of chemistry and bioactivities of EGCG, see: Nagle, D. G.; Ferreira, D.; Zhou, Y.-D. *Phytochemistry* **2006**, *67*, 1849.
- For examples, see: (a) Tachibana, H.; Koga, K.; Fujimura, Y.; Yamada, K. *Nature Struct. Mol. Biol.* **2004**, *11*, 380; (b) Fujiki, H. *The Chemical Record* **2005**, *5*, 119.
- For examples, see: (a) Nakayama, M.; Suzuki, K.; Toda, M.; Okubo, S.; Hara, Y.; Shimamura, T. *Antiviral Res.* **1993**, *21*, 289; (b) Yamaguchi, K.; Honda, M.; Ikigai, H.; Hara, Y.; Shimamura, T. *Antiviral Res.* **2002**, *53*, 19; (c) Song, J.-M.; Lee, K.-H.; Seong, B.-L. *Antiviral Res.* **2005**, *68*, 66.
- For the modulation of β -amyloid precursor protein cleavage, see: Rezai-Zadeh, K.; Shytle, D.; Sun, N.; Mori, T.; Hou, H.; Jeannot, D.; Ehrhart, J.; Townsend, K.; Zeng, J.; Morgan, D.; Hardy, J.; Town, T.; Tan, J. *J. Neurosci.* **2005**, *25*, 8807.
- For an example of asymmetric synthesis of EGCG, see: (a) Li, L.; Chan, T. H. *Org. Lett.* **2001**, *3*, 739; For examples of B- and D-ring modified analog of EGCG, see: (b) Zaveri, N. T. *Org. Lett.* **2001**, *3*, 843; (c) Wan, S. B.; Landis-Piwowar, K. R.; Kuhn, D. J.; Chen, D.; Dou, Q. P.; Chan, T. H. *Bioorg. Med. Chem.* **2005**, *13*, 2177; (d) Anderson, J. C.; Headley, C.; Stapleton, P. D.; Taylor, P. W. *Tetrahedron* **2005**, *61*, 7703; For an example of 3-amino derivative of EGCG, see: (e) Anderson, J. C.; Headley, C.; Stapleton, P. D.; Taylor, P. W. *Bioorg. Med. Chem. Lett.* **2005**, *15*, 2633.
- Recently an efficient synthesis of EGCG, including the direct formation of 2,3-*cis* stereochemistry by reductive intramolecular etherification, was reported. See: Kitade, M.; Ohno, Y.; Tanaka, H.; Takahashi, T. *Synlett* **2006**, 2827.
- For examples, see: Ref. 5a,b. In Ref. 5a, a satisfactory yield of 2,3-*cis* derivative was obtained using this strategy, but a small amount of 2,3-*cis* stereochemistry was directly constructed via an intramolecular substitution reaction of the phenolic hydroxyl group and the benzyl bromide moiety.
- To construct this ring, DABCO is the most effective. Other basic conditions using Et₃N, DBU, CsF, and NaH as well as acidic conditions employing BF₃·Et₂O, SnCl₄, and acetic acid were ineffective. These results suggest that the reaction proceeds via Baylis-Hillman type catalytic cycles. For other examples with similar ring formations, see: (a) Yan, M.-C.; Jang, Y.-J.; Yao, C.-F. *Tetrahedron Lett.* **2001**, *42*, 2717; (b) Yao, C.-F.; Jang, Y.-J.; Yan, M.-C. *Tetrahedron Lett.* **2003**, *44*, 3813.
- Bn and Ms protected hydroxyl groups to, respectively, construct rings with A-ring moieties **14** and **15**, which both possess electron donation and withdrawing groups, were unsuccessful. In both cases, only the starting aldehydes were recovered.

- For a review of Nef-type reaction, see: Ballini, R.; Petrini, M. *Tetrahedron* **2004**, *60*, 1017.
- For other examples of the direct conversion of a nitroalkene to a carbonyl group using TiCl₃, see: (a) Katoh, T.; Nishide, K.; Node, M.; Ogura, H. *Heterocycles* **1999**, *50*, 833; (b) Ballini, R.; Fiorini, D.; Palmieri, A. *Tetrahedron Lett.* **2004**, *45*, 7027.
- The reductive conditions with Zn/AcOH and Pb/AcOH afforded only oxime derivative **16**.



- The one-pot transformation of the nitrochromene derivative to the ketone derivative, which includes two steps (NaBH₄ reduction and CrCl₂ reduction in 10% aqueous HCl), has been reported. However, further selective reduction to the 2,3-*cis* catechin derivative has not been investigated. See: Rao, T. S.; Trivedi, G. K. *Indian J. Chem.* **1985**, *24B*, 1159.
- Experimental procedure for 12:* TiCl₃ (872 μ L, 1.35 mmol) was added to a solution of **10** (154 mg, 0.266 mmol) and AcONH₄ (43 mg, 0.54 mmol) in dioxane–50% AcOH (5:1, 2.5 mL) under an Ar atmosphere. The mixture was stirred for 17 h at room temperature. Then H₂O was added to the reaction mixture, extracted with EtOAc, dried over anhydrous MgSO₄, and evaporated to afford a mixture (166 mg) containing **11** as a yellow oil. The mixture (166 mg) in THF (4 mL) was cooled at –78 °C and L-Selectride (1.0 M solution in THF, 540 μ L, 0.54 mmol) was added at –78 °C under an Ar atmosphere. The mixture was allowed to warm to room temperature and stirred for 24 h. Then satd. NaHCO₃ aq was added to the reaction mixture, extracted with EtOAc, washed with brine, dried over anhydrous MgSO₄, and evaporated. The residue was purified by chromatography on a silica gel column (*n*-hexane–EtOAc, 3:1) to afford **12** (55 mg, 38%, 2 steps) as a yellow oil. Spectral data of **12**: ¹H NMR (500 MHz, CDCl₃): δ 2.95 (dd, *J* = 1.8, 16.4 Hz, 1H), 3.23 (dd, *J* = 4.3, 16.4 Hz, 1H), 4.22 (br s, 1H), 4.97 (s, 1H), 5.07 (s, 2H), 5.14 (s, 4H), 6.82 (s, 2H), 6.9–7.5 (m, 19H); MS (FAB) *m/z* 545 (M+H)⁺; HRMS calcd for C₃₆H₃₃O₅ (M+H)⁺ 545.2328. found 545.2337.
- Nakazono, M.; Ma, L.; Zaitso, K. *Tetrahedron Lett.* **2002**, *43*, 8185.
- Spectral data of **2**: ¹H NMR (270 MHz, acetone-*d*₆): δ 2.97 (d, *J* = 17.8 Hz, 1H), 3.41 (dd, *J* = 4.0, 17.8 Hz, 1H), 5.16 (s, 1H), 5.56 (br s, 1H), 6.63 (s, 2H), 6.98 (s, 2H), 6.8–7.2 (m, 4H); MS (FAB) *m/z* 427 (M+H)⁺; HRMS calcd for C₂₂H₁₉O₉ (M+H)⁺ 427.1029. found 427.1054.
- A general procedure for the Inhibition of the influenza virus infection by the analog of catechin.* Each sample (1 mg/ml) in a serum free medium (SFM) (hybridoma-SFM complete DPM, Invitrogen Corp. NY, USA) was serially diluted twofold with SFM. Seventy-five microliters of each sample dilution was mixed with 75 μ L of an influenza virus A/Memphis/1/71 (H3N2) suspension (100 FFU) in SFM and then incubated at 4 °C for 1 h. Confluent monolayers of Madine-Darby canine

kidney (MDCK) cells in 96-well microplates (Corning Costar Corporation, Cambridge, MA) were inoculated with 100 μ l of the mixture at room temperature. After 1 h at 34 °C, the inoculum was removed from each plate, the monolayers were washed three times with PBS, and incubated for 16 h at 34 °C in 100 μ l SFM. The monolayers in each well were washed three times with PBS, fixed with 50 μ l of methanol at room temperature for 5 min, and washed three more times with PBS. Infectious foci of cells were detected by focus-forming assay as previously described (a,b) using an Anti-NP monoclonal antibody and horseradish peroxidase-conjugated goat anti-mouse immunoglobulin G plus M (IgG + M) antibody. Infectious cells were defined as the mean of three counts of blue-stained cells within one well. The virus infection was determined as focus-forming units (FFU). A concentration that

caused 50% inhibition of FFU was determined by plotting the percentage inhibition against the concentration of each sample. (a) Suzuki, T.; Takahashi, T.; Guo, C.-T.; Hidari, IP. J. K.; Miyamoto, D.; Goto, H.; Kawaoka, Y.; Suzuki, Y. *J. Virol.* **2005**, *79*, 11705; (b) Aoki, C.; Hidari, IP. J. K.; Itonori, S.; Yamada, A.; Takahashi, N.; Kasama, T.; Hasebe, F.; Islam, M. A.; Hatano, K.; Matsuoka, K.; Taki, T.; Guo, C.-T.; Takahashi, T.; Sakano, Y.; Suzuki, T.; Miyamoto, D.; Sugita, M.; Terunuma, D.; Morita, K.; Suzuki, Y. *J. Biochem.* **2006**, *139*, 607.

18. (a) Kan, T.; Tominari, Y.; Morohashi, Y.; Natsugari, H.; Tomita, T.; Iwatsubo, T.; Fukuyama, T. *Chem. Commun.* **2003**, 2244; (b) Morohashi, Y.; Kan, T.; Tominari, Y.; Fuwa, H.; Okamura, Y.; Watanabe, N.; Sato, C.; Natsugari, H.; Fukuyama, T.; Iwatsubo, T.; Tomita, T. *J. Biol. Chem.* **2006**, *281*, 14670.